Profile

Jeffrey Rona

Chief Business and Financial Officer (Principal Financial and Accounting Officer), Ovid Therapeutics Inc.

Former. First published here October 28, 2026; built from records as of October 28, 2026.

Ovid Therapeutics Inc. named Charles Carter to succeed Jeffrey Rona, effective July 6, 2026.²

Seats

The seat in the record

Company	Title as filed	Standing	Filings
Ovid Therapeutics Inc. (OVID) Pharmaceutical Preparations	Chief Business and Financial Officer (Principal Financial and Accounting Officer)	Former	2

Company names link to the company's page in the record at CFO Tribune, which holds the seat history.

The record

Filing by filing, latest first

July 6, 2026effective
Ovid Therapeutics Inc. named Charles Carter to succeed Jeffrey Rona, effective July 6, 2026. Profile of Charles Carter.
[2] Filing by Ovid Therapeutics Inc., filed with the SEC on July 8, 2026. Read the filing. The record at CFO Tribune.
March 18, 202610-K filed
Jeffrey Rona signed the annual report of Ovid Therapeutics Inc. on Form 10-K as Chief Business and Financial Officer (Principal Financial and Accounting Officer), filed March 18, 2026.
/s/ Jeffrey Rona Jeffrey Rona Chief Business and Financial Officer (Principal Financial and Accounting Officer)
[1] Annual report on Form 10-K by Ovid Therapeutics Inc., filed with the SEC on March 18, 2026. Read the filing. The record at CFO Tribune.

Sources

Annual report on Form 10-K, Ovid Therapeutics Inc.. U.S. Securities and Exchange Commission, EDGAR, filed March 18, 2026. sec.gov; record.
Current report filed with the SEC, Ovid Therapeutics Inc.. U.S. Securities and Exchange Commission, EDGAR, filed July 8, 2026. sec.gov; record.

Corrections and removal

If a line here is wrong, or Jeffrey Rona wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.